ライフサイエンスコーパス: hemolytic

1 elices that are biologically promiscuous and hemolytic.

2 S (LukS-PV) does not bind to DARC and is not hemolytic.

3 The cytotoxic and hemolytic activities of the AMPs against human cells and

4 ChoP also inhibits the hemolytic activities of the related cholesterol-dependen

5 with dual 2'-O-methytransferase and putative hemolytic activities.

6 n the polar face to understand their role in hemolytic activity against human red blood cells and ant

7 zole hybrids, their time-kill studies, their hemolytic activity against murine erythrocytes, as well

8 BNPs were also tested for hemolytic activity against sheep erythrocytes.

9 is responsible for the previously described hemolytic activity associated with the choA orthologue i

10 sidues on the polar face have essentially no hemolytic activity at 1000 mug/mL (380 muM), showing for

11 e, one VHH heterodimer could reduce Shigella hemolytic activity by >80%.

12 erent C5 inhibitors simultaneously, residual hemolytic activity could be abolished.

13 lls for at least 96 h continuous exposure or hemolytic activity even at 20 mg/ml.

14 umolysin, which is associated with increased hemolytic activity in ST3081 and may contribute to incre

15 The hemolytic activity is abrogated in mutants that disrupt

16 nding that Rv0888 accounts for half of Mtb's hemolytic activity is consistent with its sphingomyelina

17 Here, we detected a stronger hemolytic activity mediated by ILY when S. intermedius P

18 Here, we used the hemolytic activity of LLO as a phenotypic marker to scre

19 glucose regulated as well as influencing the hemolytic activity of S. aureus Strains lacking the Clp

20 in Cytolysin A (ClyA) is responsible for the hemolytic activity of various Escherichia coli and Salmo

21 gative and Gram-positive bacteria, while its hemolytic activity remained around 10% or less, even aft

22 ured in human plasma, no similar increase in hemolytic activity was observed.

23 s with eukaryotic cells, as evidenced by low hemolytic activity, and protects the polypeptide backbon

24 Hemolytic activity, colonization, and virulence of S. pn

25 ddition, neither BNPs nor free BAR exhibited hemolytic activity.

26 utant expressing this mutation retained full hemolytic activity.

27 rom IPF patients showed significantly higher hemolytic activity.

28 ited proteolytic stability, with no apparent hemolytic activity.

29 vancomycin-resistant Enterococci as well as hemolytic activity.

30 and is required for normal cytotoxicity and hemolytic activity.

31 notion that a detergent effect underlies its hemolytic activity.

32 ate that exposure of cultured macrophages to hemolytic aged red blood cells, heme, or iron causes the

33 HBBE6V; HbSS), plasma EPO is elevated due to hemolytic anaemia-related hypoxia.

34 ts reveal that VG16KRKP, a non-toxic and non-hemolytic analogue of VG16, shows significant antimicrob

35 rCsMAP34 stimulated the hemolytic and bactericidal activities of serum complemen

36 against Gram-positive bacteria, but is also hemolytic and cytotoxic.

37 ium and Lactobacillus species), and were non-hemolytic and non-toxic to mammalian cell lines HepG2 an

38 y of the heme and the fact that it acts as a hemolytic and pro-inflammatory molecule.

39 y compared to W4A9, as quantified via ELISA, hemolytic, and cell-based assays, and showed improved so

40 activities, along with resistance/enzymatic, hemolytic, and cytotoxicity assays were also studied.

41 plasma as well as being hemocompatible (non-hemolytic, and poor activator of the complement system).

42 s, and signaling kinetics, during autoimmune hemolytic anemia (AIHA) and bone marrow failure.

43 Autoimmune hemolytic anemia (AIHA) is an uncommon entity that prese

44 The development of warm-antibody autoimmune hemolytic anemia (also known as warm autoimmune hemolyti

45 zed by thrombocytopenia and microangiopathic hemolytic anemia (MAHA) without an obvious cause, and ma

46 olytic anemia (also known as warm autoimmune hemolytic anemia [WAHA]) in patients with babesiosis has

47 While hemolytic anemia and an altered cytokine environment hav

48 totoxicity in in vitro models for autoimmune hemolytic anemia and antibody-mediated rejection of orga

49 ll lymphoproliferation results in autoimmune hemolytic anemia and cold-induced circulatory symptoms.

50 It is characterized by chronic hemolytic anemia and endothelial dysfunction, resulting

51 Abs (mAbs) such as rituximab and Ab-induced hemolytic anemia and immune thrombocytopenia.

52 aracterized by the combination of autoimmune hemolytic anemia and immune thrombocytopenia.

53 limited due to the use of ribavirin causing hemolytic anemia and interferon causing cytopenias.

54 ajor clinical manifestations: severe chronic hemolytic anemia and iterative vaso-occlusive crises.

55 , and thrombosis, are related to the chronic hemolytic anemia and its current management and can occu

56 The most common serious adverse events, hemolytic anemia and pharyngitis, each occurred in 2 pat

57 substantial improvement of sickle-associated hemolytic anemia and reticulocytosis, key pathophysiolog

58 merization and downstream adverse effects of hemolytic anemia and vaso-occlusion.

59 cell anemia is a unique disease dominated by hemolytic anemia and vaso-occlusive events.

60 Acute hemolytic anemia can be managed effectively provided it

61 is (HX; MIM 194380) is an autosomal-dominant hemolytic anemia characterized by primary erythrocyte de

62 Unfortunately, both drugs cause hemolytic anemia in G6PD-deficient humans.

63 The etiology of severe hemolytic anemia in most patients with recessive heredit

64 is the primary molecular event that leads to hemolytic anemia in sickle cell disease (SCD).

65 with immune thrombocytopenia and autoimmune hemolytic anemia in the setting of acute infections.

66 n disease is a difficult-to-treat autoimmune hemolytic anemia in which immunoglobulin M antibodies bi

67 Warm antibody hemolytic anemia is the most common form of autoimmune h

68 f red blood cells in human subjects, causing hemolytic anemia linked to impaired nicotinamide adenine

69 in bone marrow and spleen and is lethal in a hemolytic anemia mouse model.

70 component of the management of warm antibody hemolytic anemia not only after relapse but as soon as t

71 a or in urine, is a sign of diseases such as hemolytic anemia or urinary tract infections.

72 Hemolytic anemia recurred when drug levels were cleared

73 Finally, we chemically induce hypoxemia via hemolytic anemia resulting in HIF stabilization within c

74 Sickle cell disease (SCD), a congenital hemolytic anemia that exacts terrible global morbidity a

75 genus babesia, is characterized by nonimmune hemolytic anemia that resolves with antimicrobial treatm

76 n, now in clinical trials in warm autoimmune hemolytic anemia to lower IgG antibodies and IgG contain

77 -phosphate dehydrogenase, exhibit non-immune hemolytic anemia upon exposure to aspirin and various an

78 Hemolytic anemia was stimulated by phenylhydrazine injec

79 may develop acute and sometimes very severe hemolytic anemia when triggered by ingestion of fava bea

80 tients presenting with symptoms and signs of hemolytic anemia with a focus on RBC membrane disorders.

81 ing preexisting TTP signs; thrombocytopenia, hemolytic anemia, and organ damage could not be reversed

82 layed elevated oxidative stress, symptoms of hemolytic anemia, and premature death.

83 ion and RBC sickling include vaso-occlusion, hemolytic anemia, and stroke.

84 ection-site erythema and pyrexia, autoimmune hemolytic anemia, and suspected lack of vaccine efficacy

85 hrombosis, which result in thrombocytopenia, hemolytic anemia, and tissue ischemia.

86 ure to PCB-153, leading to oxidative stress, hemolytic anemia, and tumor development in a mouse model

87 in the liver also occurs in mouse models of hemolytic anemia, anemia of inflammation, and sickle cel

88 c disorder diagnosed by thrombocytopenia and hemolytic anemia, associated with a deficiency in von Wi

89 a gene mutated in Mendelian non-spherocytic hemolytic anemia, associated with HGB and HCT (SKAT p <

90 vere genetic blood disorder characterized by hemolytic anemia, episodic vaso-occlusion, and progressi

91 The phenotype of severe nonspherocytic hemolytic anemia, jaundice, hepatosplenomegaly, and mark

92 sodes of immune thrombocytopenia, autoimmune hemolytic anemia, or neutropenia, in addition to splenom

93 Sickle cell disease is characterized by hemolytic anemia, pain, and progressive organ damage.

94 motif of ATP11C, responsible for congenital hemolytic anemia, reduces ATP11C expression, increases r

95 ets, which account for the thrombocytopenia, hemolytic anemia, schistocytes, and tissue injury that c

96 angiopathy characterized by microangiopathic hemolytic anemia, severe thrombocytopenia, and organ isc

97 ly combine skin photosensitivity and chronic hemolytic anemia, the severity of which is related to po

98 remic syndrome is a disease characterized by hemolytic anemia, thrombocytopenia and acute renal failu

99 Microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney inj

100 hy that is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and renal failure.

101 patient program recapitulated the control of hemolytic anemia.

102 by mutations in PKLR and leads to congenital hemolytic anemia.

103 utations present with chronic nonspherocytic hemolytic anemia.

104 rocytosis (HX) and/or undiagnosed congenital hemolytic anemia.

105 athway that causes congenital nonspherocytic hemolytic anemia.

106 anemia is the most common form of autoimmune hemolytic anemia.

107 by poor pharmacokinetics and toxicity due to hemolytic anemia.

108 erythrocyte Abs and is a model of autoimmune hemolytic anemia.

109 ten present with common clinical findings of hemolytic anemia.

110 it reversed their skin photosensitivity and hemolytic anemia.

111 nti-C1s antibody sutimlimab would ameliorate hemolytic anemia.

112 eir accelerated removal from circulation and hemolytic anemia.

113 human AE1 cause several types of hereditary hemolytic anemias and/or distal renal tubular acidosis.

114 ematocrit, sickle cell disease, thalassemia, hemolytic anemias, and malaria, with both arterial and v

115 ase and other chronic hereditary or acquired hemolytic anemias.

116 red cell membrane skeleton underlie multiple hemolytic anemias.

117 tant driver of human disease, including many hemolytic anemias.

118 blood quality, as measured by physiological hemolytic assay readouts, than the conventional expert-a

119 IVIg against these pig pRBCs was measured by hemolytic assay.

120 otective function of FH in sheep erythrocyte hemolytic assays and increase cell-surface C3b depositio

121 gram-negative bacilli and regular, grey non-hemolytic colonies appearing the next day on blood agar.

122 l activity of C5 can be screened using a 50% hemolytic complement (CH50) assay, which is sensitive to

123 Although the prevention of hemolytic disease of the fetus and newborn is highly eff

124 future pregnancies, potentially resulting in hemolytic disease of the fetus and newborn.

125 mmune globulin [RhIg]) therapy has mitigated hemolytic disease of the newborn over the past half cent

126 aniofacial anomalies, chromosomal disorders, hemolytic disease, multiple gestation, third-trimester m

127 Hemopexin protects against heme toxicity in hemolytic diseases and conditions, sepsis, and sickle ce

128 Hemolytic diseases are frequently linked to multiorgan f

129 Hemolytic diseases include a variety of conditions with

130 plement system could prevent liver injury in hemolytic diseases like sickle cell disease.

131 he effects of free heme and free iron during hemolytic diseases such as sickle cell disease, dengue f

132 es (MPs) concentrate cell-free heme in human hemolytic diseases, and that heme-laden MPs have a physi

133 Hemolytic diseases, such as sickle cell anemia and thala

134 inemia cases in newborns are associated with hemolytic diseases, we emphasize here the impaired abili

135 due to malaria, sickle cell disease or other hemolytic diseases, will enable identification of high-r

136 a crucial treatment strategy in alleviating hemolytic diseases.

137 ous conditions, including from hemoglobin in hemolytic diseases.

138 nt in the liver damage and its relevance for hemolytic diseases.

139 ickle cell disease (SCD), a life-threatening hemolytic disorder, remains unknown.

140 . Dacie was known for his pioneering work on hemolytic disorders, especially paroxysmal nocturnal hem

141 Complement system activation occurs in hemolytic disorders, such as sickle cell disease, but th

142 these pathways to mitigate tissue damage of hemolytic disorders.

143 rapeutic targets for patients with sepsis or hemolytic disorders.

144 y to improve heme clearance in patients with hemolytic disorders.

145 f HU as an acute treatment for SCD and other hemolytic disorders.

146 d in a 2.5- to 4.8-fold increase in the anti-hemolytic effect but this was undetected in chemical ass

147 Similarly, OVTX-a hemolytic effect is lower than that of the reference PLT

148 Additionally, this derivative caused no hemolytic effects in murine erythrocytes and could be co

149 the mechanisms leading to organ injury upon hemolytic event could bring out therapeutic approaches.

150 However, ribavirin is associated with hemolytic events and is poorly tolerated by some patient

151 re critical for DARC binding, we studied the hemolytic function of LukE-LukS-PV chimeras, in which ar

152 with sickle cell disease (SCD), a prevalent hemolytic genetic disorder.

153 s (GBS) or Streptococcus agalactiae are beta-hemolytic gram-positive bacteria that colonize the lower

154 Group B streptococcus (GBS) is a beta-hemolytic gram-positive bacterium that colonizes the low

155 cci (GBS; Streptococcus agalactiae) are beta-hemolytic, Gram-positive bacteria that are common asympt

156 (GBS) or Streptococcus agalactiae is a beta-hemolytic, Gram-positive bacterium that is a leading cau

157 ity to detect Streptococcus group A and beta-hemolytic groups C/G using rapid antigen-negative pharyn

158 ta provide novel insights into mechanisms of hemolytic inflammation and further support perspectives

159 flammatory effects by inhibiting rapid-onset hemolytic inflammation via an NO-dependent mechanism, in

160 Relative hemolytic intensity was estimated from a composite index

161 nes (DARC) as the receptor for the S. aureus hemolytic leukocidins LukED and HlgAB.

162 esponse, measured by NGAL expression, in the hemolytic mice.

163 ed that, irrespective of the stress-induced (hemolytic or post-erythropoietin [Epo]) treatment, only

164 failure of RBCs causing hemolysis in various hemolytic pathologies.

165 eucalyptus oil induced a 13.4% increase in a hemolytic phenotype versus control, while methylated spi

166 By reverse hemolytic plaque assay, we showed that glucose-stimulate

167 re every injection given to 22 patients with hemolytic PNH while receiving eculizumab therapy.

168 activation on RBCs could play a role in the hemolytic process occurring during STEC-HUS.

169 is and whether complement is involved in the hemolytic process.

170 aim of improving antimicrobial activity and hemolytic properties, we use these reactivity difference

171 th hydroxyurea, known to decrease anemia and hemolytic rate.

172 es, UGT73F18 and UGT73F19, which glucosylate hemolytic sapogenins at the C-3 position, were identifie

173 zanhic acid, the final oxidation step of the hemolytic saponin biosynthesis branch in M. truncatula I

174 CTIVATION REGULATOR3 (TSAR3), which controls hemolytic saponin biosynthesis in developing M. truncatu

175 TSAR2 overexpression specifically boosted hemolytic saponin biosynthesis, whereas TSAR1 overexpres

176 runcatula synthesizes two types of saponins, hemolytic saponins and nonhemolytic soyasaponins, which

177 ca associated with a different strongly beta-hemolytic spirochete that has been molecularly and pheno

178 itis guidelines focus solely on group A beta-hemolytic streptococcal infection.

179 tis occurs more frequently than group A beta-hemolytic streptococcal-positive pharyngitis in a studen

180 The Lyra assay correctly detected all beta-hemolytic streptococci (group A, n = 19; group C/G, n =

181 beta-Hemolytic streptococci are frequently implicated in necr

182 beta-Hemolytic streptococci are highly prevalent in NSTIs, an

183 r cellulitis without purulent drainage, beta-hemolytic streptococci are presumed to be the predominan

184 beta-Hemolytic streptococci grew in 31%, and clindamycin resi

185 resence of clindamycin resistance among beta-hemolytic streptococci infections (1.86; 1.10-3.16).

186 ween these outcomes and the presence of beta-hemolytic streptococci or clindamycin-resistant beta-hem

187 The presence of beta-hemolytic streptococci was associated with greater risk

188 c streptococci or clindamycin-resistant beta-hemolytic streptococci were calculated using log-binomia

189 occus aureus, Streptococcus pneumoniae, beta-hemolytic streptococci, vancomycin-resistant Enterococcu

190 r risk of limb loss among patients with beta-hemolytic streptococci-particularly clindamycin-resistan

191 receptor in the single MPhi response to beta-hemolytic streptococci.

192 Rapid detection of group A beta-hemolytic streptococcus (GAS) is used routinely to help

193 ganisms are identified, most are due to beta-hemolytic Streptococcus and Staphylococcus aureus.

194 The pathogenic role of beta-hemolytic Streptococcus dysgalactiae in the equine host

195 Group A beta-hemolytic streptococcus was detected in 10.3% of patient

196 plates for isolation of the large-zone beta-hemolytic streptococcus.

197 deficiency promotes AKI in sickle mice under hemolytic stress.

198 purified hemopexin prior to the induction of hemolytic stress.

199 ile alpha-hemolysin was produced but was not hemolytic, suggesting that hAMs alter toxin activity.

200 st promising compounds were found to be less hemolytic than the FDA-approved antifungal agent voricon

201 Also, they were both relatively less hemolytic than the known membrane targeting antibiotic g

202 ssing cells to ethidium bromide; and was non-hemolytic to human red blood cells.

203 antibodies against RBC non-ABO Ags can cause hemolytic transfusion reactions and limit availability o

204 s because p erythrocytes may pose a risk for hemolytic transfusion reactions due to their elevated PX

205 Thus, understanding of hemolytic transfusion reactions is generated through cli

206 s, potentially resulting in acute or delayed hemolytic transfusion reactions or in difficulty locatin

207 Antibody-induced hemolytic transfusion reactions were first described ove

208 increase the probability of life-threatening hemolytic transfusion reactions, not all patients genera

209 inst RBCs can cause life-threatening delayed hemolytic transfusion reactions.

210 ted acute lung injury, and acute and delayed hemolytic transfusion reactions.

211 ed decreases in some adverse events, such as hemolytic transfusion reactions.

212 a indicate that eucalyptus oil may also be a hemolytic trigger in those with G6PD deficiency.

213 Collectively, our findings point to hemolytic type I E. coli as a candidate causative factor

214 te similar to that of patients with atypical hemolytic uremic syndrome (51.5%).

215 complement-related diseases such as atypical hemolytic uremic syndrome (aHUS) and age-related macular

216 linked to the human kidney diseases atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy.

217 in, have been well characterized in atypical hemolytic uremic syndrome (aHUS) but have been less well

218 Patients with atypical hemolytic uremic syndrome (aHUS) develop a thrombotic mi

219 escribe an assay that could convert atypical hemolytic uremic syndrome (aHUS) from a diagnosis of exc

220 eneic HSCT shares similarities with atypical hemolytic uremic syndrome (aHUS) in the underlying patho

221 Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microan

222 Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microan

223 Atypical hemolytic uremic syndrome (aHUS) is an orphan disease wi

224 Atypical hemolytic uremic syndrome (aHUS) is characterized by com

225 Atypical hemolytic uremic syndrome (aHUS) is classically describe

226 Atypical hemolytic uremic syndrome (aHUS) is frequently associate

227 Atypical hemolytic uremic syndrome (aHUS) is life-threatening con

228 The pathogenesis of atypical hemolytic uremic syndrome (aHUS) is strongly linked to d

229 ions in complement C3 identified in atypical hemolytic uremic syndrome (aHUS) patients cause dysregul

230 he thrombotic microangiopathy (TMA) atypical hemolytic uremic syndrome (aHUS) resulted in the success

231 iseases C3 glomerulopathy (C3G) and atypical hemolytic uremic syndrome (aHUS) strongly associate with

232 Atypical hemolytic uremic syndrome (aHUS), a rare form of thrombo

233 h was described in association with atypical hemolytic uremic syndrome (aHUS), also confers high risk

234 mal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and various glomerular

235 a an alternative pathway results in atypical hemolytic uremic syndrome (aHUS), the prototypes of thro

236 ed CFH, whereas R53H-CFH, linked to atypical hemolytic uremic syndrome (aHUS), was defective in C3bBb

237 nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).

238 s is central to the pathogenesis of atypical hemolytic uremic syndrome (aHUS).

239 ly, to diagnose complement-mediated atypical hemolytic uremic syndrome (aHUS; a diagnosis of exclusio

240 induce the symptoms of the life-threatening hemolytic uremic syndrome (HUS) and are the main virulen

241 hrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) are appropriately at the

242 104:H4 caused an outbreak with >800 cases of hemolytic uremic syndrome (HUS) in Germany, including 90

243 Hemolytic uremic syndrome (HUS) is a thrombotic microang

244 Atypical hemolytic uremic syndrome (HUS) is associated with high

245 Hemolytic uremic syndrome (HUS) is the life-threatenig s

246 Hemolytic uremic syndrome (HUS) occurred in 12 patients

247 Identifying hemolytic uremic syndrome (HUS) risk factors is needed t

248 tion status, the development and severity of hemolytic uremic syndrome (HUS), and adverse outcomes in

249 e progresses to hemorrhagic colitis (HC) and hemolytic uremic syndrome (HUS), due to the expression o

250 role in the pathogenesis of postenteropathic hemolytic uremic syndrome (HUS), most commonly caused by

251 moxetumomab pasudotox for 10 doses developed hemolytic uremic syndrome (HUS), thrombotic microangiopa

252 hea, dysentery, hemorrhagic colitis (HC) and hemolytic uremic syndrome (HUS).

253 infection is associated with development of hemolytic uremic syndrome (HUS).

254 lar (mostly congenital; n = 650), glomerular-hemolytic uremic syndrome (HUS; n = 49), or glomerular-n

255 to severe renal diseases, including atypical hemolytic uremic syndrome and C3 glomerulopathies, and a

256 complement-driven diseases such as atypical hemolytic uremic syndrome and catastrophic antiphospholi

257 associated with the renal diseases atypical hemolytic uremic syndrome and dense deposit disease and

258 the major foodborne pathogens that can cause hemolytic uremic syndrome and infantile diarrhea, respec

259 lation-mediated endothelial damage: atypical hemolytic uremic syndrome and thrombotic thrombocytopeni

260 the basis of clinical presentation (atypical hemolytic uremic syndrome as thrombotic microangiopathy)

261 afety of anticomplement therapy for atypical hemolytic uremic syndrome during pregnancy, and implicat

262 Hemolytic uremic syndrome is a disease characterized by

263 FHR) genes and autoantibody-positive form of hemolytic uremic syndrome is characterized by the presen

264 rne pathogen that causes bloody diarrhea and hemolytic uremic syndrome throughout the world.

265 In hemolytic uremic syndrome with brain involvement symptom

266 ge-related macular degeneration and atypical hemolytic uremic syndrome, a form of thrombotic microang

267 tations in FH and MCP are linked to atypical hemolytic uremic syndrome, a type of thrombotic microang

268 states; 104 were hospitalized, 28 developed hemolytic uremic syndrome, and 5 died.

269 states; 104 were hospitalized, 28 developed hemolytic uremic syndrome, and five died.

270 these genes have been described in atypical hemolytic uremic syndrome, arising commonly through nona

271 nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome, blocks the terminal complemen

272 sent in patients with the autoimmune form of hemolytic uremic syndrome, is involved in B cell regulat

273 s age-related macular degeneration, atypical hemolytic uremic syndrome, membranoproliferative glomeru

274 nal hemoglobinuria, cold agglutinin disease, hemolytic uremic syndrome, nephropathies, HELLP syndrome

275 E. coli O157:H7 can cause bloody diarrhea, hemolytic uremic syndrome, or even death.

276 a spectrum of rare diseases such as atypical hemolytic uremic syndrome, thrombotic thrombocytopenic p

277 f the C3b-binding sites and causing atypical hemolytic uremic syndrome, we found that it detached mor

278 Compared with wild type FH19-20, atypical hemolytic uremic syndrome-associated mutants were less a

279 s severe bloody diarrhea, renal failure, and hemolytic uremic syndrome.

280 (FH(R/R)) share features with human atypical hemolytic uremic syndrome.

281 induced by sera from patients with atypical hemolytic uremic syndrome.

282 eadly thrombomicroangiopathy called atypical hemolytic uremic syndrome.

283 xysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

284 aging findings in a four-month-old male with hemolytic uremic syndrome.

285 renal biopsy of a child with EHEC-associated hemolytic uremic syndrome.

286 sease, including hemorrhagic colitis and the hemolytic uremic syndrome.

287 nary tract infections, as well as sepsis and hemolytic uremic syndrome.

288 mplications, such as hemorrhagic colitis and hemolytic uremic syndrome.

289 rne pathogen causing hemorrhagic colitis and hemolytic uremic syndrome.

290 R4, and CFHR5 genes are reported in atypical hemolytic uremic syndrome.

291 ase outcomes such as hemorrhagic colitis and hemolytic uremic syndrome.

292 disease ranging from hemorrhagic colitis to hemolytic uremic syndrome.

293 wide associated with hemorrhagic colitis and hemolytic uremic syndrome.

294 associated with the related disease atypical hemolytic uremic syndrome; 6.8% in cases versus 5.9% in

295 Hemolytic-uremic syndrome (HUS) is a thrombotic microang

296 life-threatening sequela of infection called hemolytic-uremic syndrome (HUS) than isolates that make

297 family of cytotoxic proteins that can cause hemolytic-uremic syndrome (HUS), a thrombotic microangio

298 ions, including hemorrhagic colitis (HC) and hemolytic-uremic syndrome (HUS), which is the most commo

299 ding thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome, have been reported to have a

300 ogen and is the cause of bloody diarrhea and hemolytic-uremic syndrome.